Novo Nordisk faces pivotal Q1 earnings amid a 36% YTD stock drop, competitive pressure from Eli Lilly, and a deep valuation divide as analysts remain split on recovery.<\/p>\n
Novo Nordisk enters a pivotal week with its first-quarter earnings due Wednesday, caught between a brutal valuation reset and tentative signs of stabilization. The Danish drugmaker\u2019s shares have clawed back roughly 17 percent from a 52-week low of $35.12, closing April at $42.22 \u2014 but the recovery masks deep fractures in investor confidence.<\/p>\n
The Lilly Effect Cuts Both Ways<\/p>\n
Eli Lilly\u2019s blockbuster quarterly report provided an unexpected tailwind for its Danish rival. Barclays described Lilly\u2019s decision to raise its 2026 revenue guidance by $2 billion as neutral to positive for Novo Nordisk, arguing that it validates continued expansion of the GLP-1 market. Yet Lilly\u2019s surging Mounjaro sales \u2014 up 125 percent in the first quarter \u2014 also underscore the competitive pressure bearing down on Novo\u2019s Wegovy and Ozempic franchises.<\/p>\n
A more nuanced picture emerges from prescription data. Lilly\u2019s newly approved oral pill Foundayo generated roughly 3,700 prescriptions in its second week on the market. By contrast, Novo Nordisk\u2019s oral GLP-1 therapy notched over 18,000 prescriptions in a comparable period \u2014 a data point that has temporarily eased fears about Wegovy\u2019s market position.<\/p>\n
A Deep Valuation Divide<\/p>\n
The stock\u2019s trajectory tells a stark story. Down roughly 36 percent year-to-date, Novo Nordisk now trades at about 12 times earnings \u2014 a fraction of Lilly\u2019s 26-times multiple. Morningstar pegs the fair value at just $18, implying the current share price of roughly $40 to $41 carries an 85 percent premium. That assessment underscores just how inflated valuations became during the 2024 GLP-1 euphoria.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n Wall Street remains sharply divided. Six analysts maintain buy ratings with an average price target near $58, betting that long-term growth potential outweighs near-term headwinds. But recent downgrades tell a different tale: Citi cut its rating, Bernstein initiated with \u201cunderperform,\u201d and the consensus price target has been slashed by more than 21 percent over the past three months. Goldman Sachs holds a $41 target \u2014 barely above the current level \u2014 while Kepler Capital reiterated \u201chold\u201d in late April.<\/p>\n The Numbers That Matter<\/p>\n The Q1 report is expected to deliver sobering figures. Analysts forecast an 8 percent year-over-year revenue decline and a 16 percent drop in earnings per share. For the full year, Novo Nordisk itself projects adjusted revenue growth between negative 5 percent and negative 13 percent at constant exchange rates.<\/p>\n Morningstar warns that US prices for semaglutide could fall more than 20 percent in 2026, driven by Medicare Part D negotiations and most-favored-nation clauses. That would hit margins harder and sooner than previously modeled.<\/p>\n Counterweights to the Gloom<\/p>\n Several factors offer support. The FDA recently proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk substance list \u2014 a move against compounding pharmacies that sent Novo Nordisk shares up nearly 5 percent. Conversely, Health Canada\u2019s approval of an injectable semaglutide generic has spooked investors, with some analysts viewing it as a potential precedent for other markets.<\/p>\n Novo Nordisk\u2019s partnership with OpenAI, announced in mid-April, aims to integrate artificial intelligence across research, manufacturing, and supply chain operations by the end of 2026. The announcement lifted the stock roughly 2.8 percent, though financial terms were not disclosed.<\/p>\n